

ASX & MEDIA RELEASE 23 JANUARY, 2012

NOVOGEN REGAINS COMPLIANCE WITH NASDAQ LISTING RULE

Novogen Limited (ASX: NRT NASDAQ:NVGN) - In addition to the listing of its ordinary shares on the Australian Stock Exchange, the Company has an American Depository Receipt (ADR) program with the ADRs listed on the Nasdaq Capital Market.

The Company had previously announced to the market on 25 July, 2011 that it had received a notice from Nasdaq advising that it was no longer in compliance with the Nasdaq listing requirements for its ADR program and allowing 180 days in which to correct the non-compliance.

On 18 January, 2012 the Company received confirmation from Nasdaq that for the ten consecutive business days, from 3 January, 2012 to 17 January, 2012, the closing bid price of the Company's ADRs had been at US\$1.00 or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

This notification from the Nasdaq Stock Market has no bearing on the ASX listing.

About Novogen Limited

Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR : NOVOGEN LIMITED

LISTINGS : ASX (CODE NRT), NASDAQ (CODE NVGN).

FOR FURTHER

INFORMATION : MR BILL RUECKERT, CHAIRMAN, NOVOGEN LIMITED

TEL (02) 9878 0088 http://www.novogen.com

ISSUED BY : WESTBROOK COMMUNICATIONS

CONTACT: IAN WESTBROOK TEL (02) 9231 0922, 0407 958 137